Agostinetto Elisa, Montemurro Filippo, Puglisi Fabio, Criscitiello Carmen, Bianchini Giampaolo, Del Mastro Lucia, Introna Martino, Tondini Carlo, Santoro Armando, Zambelli Alberto
Academic Trials Promoting Team, Institut Jules Bordet, L'Université Libre de Bruxelles (U.L.B), 1070 Brussels, Belgium.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
Cancers (Basel). 2022 Apr 25;14(9):2136. doi: 10.3390/cancers14092136.
Breast cancer is the most common malignancy among women worldwide, and HER2-positive breast cancer accounts for approximately 15% of all breast cancer diagnoses. The advent of HER2-targeting therapies has dramatically improved the survival of these patients, significantly reducing their risk of recurrence and death. However, as a significant proportion of patients ultimately develop resistance to these therapies, it is extremely important to identify new treatments to further improve their clinical outcomes. Immunotherapy has revolutionized the treatment and history of several cancer types, and it has already been approved as a standard of care for patients with triple-negative breast cancer. Based on a strong preclinical rationale, immunotherapy in HER2-positive breast cancer represents an intriguing field that is currently under clinical investigation. There is a close interplay between HER2-targeting therapies (both approved and under investigation) and the immune system, and several new immunotherapeutic strategies, including immune checkpoint inhibitors, CAR-T cells and therapeutic vaccines, are being studied in this disease. In this narrative review, we discuss the clinical evidence and the future perspectives of immunotherapy for patients with HER2-positive breast cancer.
乳腺癌是全球女性中最常见的恶性肿瘤，HER2阳性乳腺癌约占所有乳腺癌诊断病例的15%。HER2靶向治疗的出现显著提高了这些患者的生存率，显著降低了他们复发和死亡的风险。然而，由于相当一部分患者最终会对这些治疗产生耐药性，因此确定新的治疗方法以进一步改善其临床结局极为重要。免疫疗法已经彻底改变了几种癌症类型的治疗方式和历史，并且它已经被批准作为三阴性乳腺癌患者的标准治疗方法。基于强有力的临床前理论依据，HER2阳性乳腺癌的免疫疗法是一个目前正在临床研究中的有趣领域。HER2靶向治疗（包括已获批的和正在研究的）与免疫系统之间存在密切的相互作用，并且几种新的免疫治疗策略，包括免疫检查点抑制剂、嵌合抗原受体T细胞（CAR-T细胞）和治疗性疫苗，正在针对这种疾病进行研究。在这篇叙述性综述中，我们讨论了HER2阳性乳腺癌患者免疫治疗的临床证据和未来前景。
